How Is Cybin Inc. (NYSE:CYBN) Advancing Psychedelic-Based Therapies?

2 min read | March 04, 2025 12:00 AM PST | By Team Kalkine Media

Google News:

How Is Cybin Inc. (NYSE:CYBN) Advancing Psychedelic-Based Therapies? — Image source: Shutterstock

Recent News

Darden Restaurants Earnings Optimism Sparks Fresh Market Attention

Can Rising Demand Reshape Atlas Energy Solutions’ Outlook?

DTE Energy’s Grid Expansion Strategy Draws Fresh Investor Attention

Intercontinental Exchange AI Expansion Sparks Fresh Market Interest

Make Kalkine Media
My Trusted Source

Highlights

Global Retirement Partners LLC acquired 5,250 shares in Cybin Inc., valued at around $46,000, as per SEC filings.

Recent research reports from Canaccord Genuity Group and HC Wainwright have adjusted price targets while maintaining positive sentiment.

Cybin Inc. is advancing psychedelic-based therapeutics with multiple drugs in different clinical trial stages.

Institutional Transactions

Cybin Inc. (NYSE:CYBN) has continued to gain attention from institutional firms, with Global Retirement Partners LLC securing a new position in the company. The acquisition, amounting to 5,250 shares and valued at approximately $46,000, was disclosed in a recent Securities and Exchange Commission (SEC) filing. This move aligns with broader institutional interest in the biopharmaceutical company.

Market Research Updates

Various research firms have provided updated assessments of Cybin Inc. Canaccord Genuity Group revised its price objective, adjusting it from $86.00 to $73.00 while maintaining a rating for the stock. Similarly, HC Wainwright modified its previous price target from $190.00 to $150.00, with its report continuing to reflect optimism regarding Cybin’s position in the sector.

Stock Performance and Market Position

Cybin Inc. recently opened at $8.16, with fluctuations in its stock performance over the past year. The company maintains a market capitalization of $174.27 million and has a price-to-earnings (P/E) ratio of -1.86. Its beta of 0.46 suggests a relatively moderate correlation with broader market movements. Trading activity has placed the company within a range of $6.50 to $19.85 over the past year.

Advancements in Therapeutics

Operating as a clinical-stage biopharmaceutical entity, Cybin Inc. specializes in psychedelic-based therapeutics aimed at addressing mental health conditions. The company has been developing CYB003, a deuterated psilocybin analog currently progressing through phase 1/2a clinical trials for major depressive disorder (MDD) while also undergoing preclinical trials for alcohol use disorder.

CYB004, another lead candidate, focuses on treating generalized anxiety disorders, having successfully completed phase 2 trials. Additionally, SPL028 and SPL026 have made measurable progress in both clinical and preclinical stages.

Industry Standing and Innovation

Cybin Inc. continues to expand its research efforts, leveraging innovative approaches to psychedelic-based therapies. With multiple programs in development, the company remains engaged in advancing solutions for mental health challenges while strengthening its presence within the biopharmaceutical landscape.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.